Genomic characterization of respiratory syncytial virus 2022-2023 outbreak in Washington State, USA

Stephanie Goya; Jaydee Sereewit; Daniel Pfalmer; Tien V. Nguyen; Shah A. K. Mohamed Bakhash; Elizabeth B. Sobolik; Alexander L. Greninger

doi:10.1101/2022.12.12.22283375

Abstract

Mitigation measures against the COVID-19 pandemic affected the RSV seasonality and led to an unexpectedly high number of RSV cases in Washington State since October 2022. Here we describe the RSV genomic characteristics and evolutionary relationship of 2022 outbreak compared to the previous RSV outbreaks in the region and globally.

Competing Interest Statement

ALG reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research support from Gilead and Merck, outside of the described work. The other authors declare that they have no conflict of interest.

Funding Statement

This study received no specific funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the UW Institutional Review Board with a consent waiver (STUDY00000408).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

RSV consensus genomes are available at NCBI GenBank under the accession numbers OP890312 - OP890350 and OP965698 - OP965712. Sequencing reads are available associated with NCBI BioProject PRJNA907066.

https://github.com/greninger-lab/RSV-WA-2022

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.